Molecular Biology Reports

, Volume 41, Issue 2, pp 977–986 | Cite as

Inhibition of human glioma U251 cells growth in vitro and in vivo by hydroxyapatite nanoparticle-assisted delivery of short hairpin RNAs against SATB1

  • Sheng-Hua Chu
  • Zhang-Ming Zhou
  • Dong-Fu Feng
  • Yan-Bin Ma


Special AT-rich sequence-binding protein-1 (SATB1) has been reported to be over-expressed in many human tumors and knockdown of SATB1 can inhibit tumor growth. The present study was designed to determine the role of SATB1 in the growth of human glioma U251 cells using the plasmid-based SATB1 short hairpin RNA (shRNA) delivered by hydroxyapatite nanoparticles in vitro and in vivo. The in vitro growth, invasion and angiogenesis assays of human glioma U251 cells were done. U251 cells tumor blocks were transplanted into the nude mice. CaCl2-modified hydroxyapatite nanoparticles carrying shRNA-SATB1 plasmids were injected into the tumors. The apoptosis of the tumor U251 cells was examined with TUNEL assay and flow cytometer (FCM). The tumor growth and immunohistochemistry were measured. The expression level of SATB1 mRNA was investigated by RT-PCR. The expression levels of SATB1, Cyclin D1, MMP-2, VEGF, Bax and Caspase-9 protein were determined by western blot analysis. The results showed that hydroxyapatite nanoparticles-delivered shRNA-SATB1 could significantly inhibit the growth, invasion and angiogenesis of U251 cells in vitro and the growth of U251 cells in vivo. FCM results showed that Nano HAP-shRNA-SATB1-induced apoptosis (up to 67.8 %). SATB1 expression was strongly down-regulated in the tumor U251 cells. Cyclin D1, MMP-2 and VEGF were also down-regulated in the tumor tissues that also displayed significant increased in Bax expression and Caspase-9 activity. These results show that Nano HAP-shRNA-SATB1 can inhibit the growth of human glioma U251 cells in vitro and in vivo, and hydroxyapatite nanoparticles can be used for the in vitro and in vivo delivery of plasmid-based shRNAs into U251 cells.


Glioma SATB1 Growth Hydroxyapatite nanoparticle RNA interference 



This work was supported by Grants from the Innovation Program of Shanghai Municipal Education Commission (12YZ046) and the New One Hundred Person Project of Shanghai Jiao Tong University of School of Medicine (10XBR01).


  1. 1.
    Kouzarides T (1999) Histone acetylases and deacetylases in cell proliferation. Curr Opin Genet Dev 9:40–48CrossRefPubMedGoogle Scholar
  2. 2.
    Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T (1992) A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell 70:631–645CrossRefPubMedGoogle Scholar
  3. 3.
    Hanker LC, Karn T, Mavrova-Risteska L, Ruckhäberle E, Gaetje R, Holtrich U, Kaufmann M, Rody A, Wiegratz I (2011) SATB1 gene expression and breast cancer prognosis. Breast 20:309–313CrossRefPubMedGoogle Scholar
  4. 4.
    Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, Liu K, Wu K, Tong Q (2010) Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS 118:855–863CrossRefPubMedGoogle Scholar
  5. 5.
    Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, Jiang PC (2012) Upregulation of SATB1 is associated with the development and progression of glioma. J Transl Med 10:149CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Chu SH, Ma YB, Feng DF, Li ZQ, Jiang PC (2013) Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme. Mol Med Rep 7:139–143PubMedGoogle Scholar
  7. 7.
    Chu SH, Feng DF, Zhang H, Chen ET, Duan ZX, Li XY, Li J, Ma YB, Zhu ZA, Qiu JH (2009) c-Met-targeted RNA interference inhibits growth and metastasis of glioma U251 cells in vitro. J Neurooncol 93:183–189CrossRefPubMedGoogle Scholar
  8. 8.
    Yamada M, Ueno T, Tsukimura N, Ikeda T, Nakagawa K, Hori N, Suzuki T, Ogawa T (2012) Bone integration capability of nanopolymorphic crystalline hydroxyapatite coated on titanium implants. Int J Nanomed 7:859–873Google Scholar
  9. 9.
    Singh MK, Gracio J, LeDuc P, Gonçalves PP, Marques PA, Gonçalves G, Marques F, Capela e Silva VS, Capela F, Reis J, Potes J, Sousa A (2010) Integrated biomimetic carbon nanotube composites for in vivo systems. Nanoscale 2:2855–2863CrossRefPubMedGoogle Scholar
  10. 10.
    Fernandez JM, Molinuevo MS, Cortizo MS, Cortizo AM (2011) Development of an osteoconductive PCL-PDIPF-hydroxyapatite composite scaffold for bone tissue engineering. J Tissue Eng Regen Med 5:e126–e135CrossRefPubMedGoogle Scholar
  11. 11.
    Ye F, Guo HF, Zhang HJ, He XL (2010) Polymeric micelle-templated synthesis of hydroxyapatite hollow nanoparticles for a drug delivery system. Acta Biomater 6:2212–2218CrossRefPubMedGoogle Scholar
  12. 12.
    Liu H, Xi P, Xie G, Chen F, Li Z, Bai D, Zeng Z (2011) Biocompatible hydroxyapatite nanoparticles as a redox luminescence switch. J Biol Inorg Chem 16:1135–1140CrossRefPubMedGoogle Scholar
  13. 13.
    Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, Langer R, Farokhzad OC (2008) Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 26:442–449CrossRefPubMedGoogle Scholar
  14. 14.
    Xu J, Xu P, Li Z, Huang J, Yang Z (2012) Oxidative stress and apoptosis induced by hydroxyapatite nanoparticles in C6 cells. J Biomed Mater Res A 100:738–745CrossRefPubMedGoogle Scholar
  15. 15.
    Liang ZW, Guo BF, Li Y, Li XJ, Li X, Zhao LJ, Gao LF, Yu H, Zhao XJ, Zhang L, Yang BX (2011) Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo. Asian J Androl 13:481–486CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Chu SH, Feng DF, Ma YB, Li ZQ (2012) Hydroxyapatite nanoparticles inhibit the growth of human glioma cells in vitro and in vivo. Int J Nanomed 7:3659–3666CrossRefGoogle Scholar
  17. 17.
    Chu SH, Zhu ZA, Yuan XH, Li ZQ, Jiang PC (2006) In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides. J Neurooncol 80:143–149CrossRefPubMedGoogle Scholar
  18. 18.
    Chu SH, Ma YB, Feng DF, Zhang H, Qiu JH, Zhu ZA (2012) Effect of 5-Aza-2′-deoxycytidine on SLC22A18 in glioma U251 cells. Mol Med Rep 5:138–141PubMedGoogle Scholar
  19. 19.
    Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T (2008) SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 452:187–193CrossRefPubMedGoogle Scholar
  20. 20.
    Ma C, Zhang J, Durrin LK, Lv J, Zhu D, Han X, Sun Y (2007) The BCL2 major breakpoint region (mbr) regulates gene expression. Oncogene 26:2649–2657CrossRefPubMedGoogle Scholar
  21. 21.
    Chu SH, Feng DF, Ma YB, Zhang H, Zhu ZA, Li ZQ, Jiang PC (2011) Promoter methylation and downregulation of SLC22A18 are associated with the development and progression of human glioma. J Transl Med 9:156CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Serbetçi K, Uysal O, Erkasap N, Köken T, Baydemir C, Erkasap S (2012) Anti-apoptotic and antioxidant effect of leptin on CCl4-induced acute liver injury in rats. Mol Biol Rep 39:1173–1180CrossRefPubMedGoogle Scholar
  23. 23.
    Demurtas A, Aliberti S, Bonello L, Di Celle PF, Cavaliere C, Barreca A, Novero D, Stacchini A (2011) Usefulness of multiparametric flow cytometry in detecting composite lymphoma: study of 17 cases in a 12-year period. Am J Clin Pathol 135:541–555CrossRefPubMedGoogle Scholar
  24. 24.
    Wang E, Hutchinson CB, Huang Q, Lu CM, Crow J, Wang FF, Sebastian S, Rehder C, Lagoo A, Horwitz M, Rizzieri D, Yu J, Goodman B, Datto M, Buckley P (2011) Donor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature. Am J Clin Pathol 135:525–540CrossRefPubMedGoogle Scholar
  25. 25.
    Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, Jiang PC (2012) Correlation of low SLC22A18 expression with poor prognosis in patients with glioma. J Clin Neurosci 19:95–98CrossRefPubMedGoogle Scholar
  26. 26.
    Zhao L, Ju D, Gao Q, Zheng X, Yang G (2012) Over-expression of Nkx2.5 and/or cardiac α-actin inhibit the contraction ability of ADSCs-derived cardiomyocytes. Mol Biol Rep 39:2585–2595CrossRefPubMedGoogle Scholar
  27. 27.
    Chu SH, Zhang H, Ma YB, Feng DF, Zhu ZA, Yuan XH, Li ZQ (2007) c-Met antisense oligodeoxynucleotides as a novel therapeutic agent for glioma: in vitro and in vivo studies of uptake, effects, and toxicity. J Surg Res 141:284–288CrossRefPubMedGoogle Scholar
  28. 28.
    Li K, Cai R, Dai BB, Zhang XQ, Wang HJ, Ge SF, Xu WR, Lu J (2007) SATB1 regulates SPARC expression in K562 cell line through binding to a specific sequence in the third intron. Biochem Biophys Res Commun 356:6–12CrossRefPubMedGoogle Scholar
  29. 29.
    Chu SH, Feng DF, Ma YB, Zhang H, Zhu ZA, Li ZQ, Zhang ZH (2011) Expression of HGF and VEGF in the cerebral tissue of adult rats with chronic hydrocephalus after subarachnoid hemorrhage. Mol Med Rep 4:785–791PubMedGoogle Scholar
  30. 30.
    Liu B, Wang L, Shen LL, Shen MZ, Guo XD, Wang T, Liang QC, Wang C, Zheng J, Li Y, Jia LT, Zhang H, Gao GD (2012) RNAi-mediated inhibition of presenilin 2 inhibits glioma cell growth and invasion and is involved in the regulation of Nrg1/ErbB signaling. Neuro Oncol 14:994–1006CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Chen L, Han L, Zhang K, Shi Z, Zhang J, Zhang A, Wang Y, Song Y, Li Y, Jiang T, Pu P, Jiang C, Kang C (2012) VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1α/VEGF and β-catenin/Tcf-4 signaling. Neuro Oncol 14:1026–1036CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Raghu H, Gondi CS, Dinh DH, Gujrati M, Rao JS (2011) Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch-1 receptor. Mol Cancer 10:130CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Krangel MS (2007) T cell development: better living through chromatin. Nat Immunol 8:687–694CrossRefPubMedGoogle Scholar
  34. 34.
    Choi JY, Pratap J, Javed A, Zaidi SK, Xing L, Balint E, Dalamangas S, Boyce B, van Wijnen AJ, Lian JB, Stein JL, Jones SN, Stein GS (2001) Subnuclear targeting of Runx/Cbfa/AML factors is essential for tissue specific differentiation during embryonic development. Proc Natl Acad Sci USA 98:8650–8655CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Cai S, Lee CC, Kohwi-Shigematsu T (2006) SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet 38:1278–1288CrossRefPubMedGoogle Scholar
  36. 36.
    Cai R, Xu W, Dai B, Cai X, Xu R, Lu J (2010) SATB1 binds an intronic MAR sequence in human PI3kgamma in vitro. Mol Biol Rep 37:1461–1465CrossRefPubMedGoogle Scholar
  37. 37.
    Lu PY, Xie F, Woodle MC (2005) In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet 54:117–142PubMedGoogle Scholar
  38. 38.
    Kim WJ, Kim SW (2009) Efficient siRNA delivery with non-viral polymeric vehicles. Pharm Res 26:657–666CrossRefPubMedGoogle Scholar
  39. 39.
    Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T (2012) Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol 14:109–116CrossRefPubMedGoogle Scholar
  40. 40.
    Wang WJ, Meng ZL, Mo YC, Liu JW, Sun CC, Hu SS, Zhang H (2012) Unloading the infarcted heart affect MMPs–TIMPs axis in a rat cardiac heterotopic transplantation model. Mol Biol Rep 39:277–283CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Sheng-Hua Chu
    • 1
  • Zhang-Ming Zhou
    • 2
  • Dong-Fu Feng
    • 1
  • Yan-Bin Ma
    • 1
  1. 1.Department of Neurosurgery, Shanghai 3rd People’s Hospital, School of MedicineShanghai Jiao Tong UniversityShanghaiChina
  2. 2.Department of NeurosurgeryDujiangyan Medical CenterChengduChina

Personalised recommendations